Class summary at a glance.

Every drug in the Nucleoside Analog Antiviral class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $2.8Mcombined across class
Total Rx claims: 19K14K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Trifluridine

16K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2001-05-14

1 generic mfrs 0 plans require PA

Low NADAC$22.20

→

Avg plan cost$22.20

Part D spend $2.4M 1× spread, current vs floor

Class share

85%

of class CY24 spend

View profile →

Ribavirin

Brand: Virazole · 3K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1986-01-01

4 generic mfrs 8 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $413762

Class share

15%

of class CY24 spend

View profile →

Trifluridine and Tipiracil

Brand: LONSURF · — Part D claims (CY24) · First FDA approval: 2015-09-22

2 generic mfrs 652 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.